Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy
Version of Record online: 12 JUL 2004
Copyright © 2004 Wiley-Liss, Inc.
Pediatric Blood & Cancer
Volume 43, Issue 7, pages 780–784, December 2004
How to Cite
Fisher, M. J., Lange, B. J., Needle, M. N., Janss, A. J., Shu, H.-K. G., Adamson, P. C. and Phillips, P. C. (2004), Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy. Pediatr. Blood Cancer, 43: 780–784. doi: 10.1002/pbc.20132
- Issue online: 27 OCT 2004
- Version of Record online: 12 JUL 2004
- Manuscript Accepted: 24 MAY 2004
- Manuscript Received: 10 MAR 2004
In adult patients, amifostine appears to ameliorate cisplatin-related nephrotoxicity and ototoxicity. We assessed the safety and efficacy of amifostine in 11 children with newly diagnosed medulloblastoma/primitive neuroectodermal tumor treated with radiotherapy and vincristine, lomustine, and cisplatin. Amifostine was administered immediately prior to and 4 hr into the cisplatin infusion. Amifostine caused assymptomatic hypotension and hypocalcemia in 18 and 82% of patients, respectively. Despite amifostine use, 78% of patients developed significant ototoxicity. Although relatively well tolerated, amifostine does not appear to have a major impact on ameliorating the risk of developing significant nephro- and ototoxicity in children with medulloblastoma. Larger studies will help clarify these findings. Pediatr Blood Cancer 2004;43:780–784. © 2004 Wiley-Liss, Inc.